NM_006073.4:c.1783G>A

Variant summary

Our verdict is Uncertain significance. The variant received 4 ACMG points: 4P and 0B. PP3_Strong

The NM_006073.4(TRDN):​c.1783G>A​(p.Asp595Asn) variant causes a missense, splice region change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000268 in 1,565,760 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Uncertain significance (★★).

Frequency

Genomes: 𝑓 0.000026 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000027 ( 0 hom. )

Consequence

TRDN
NM_006073.4 missense, splice_region

Scores

3
16
Splicing: ADA: 1.000
2

Clinical Significance

Uncertain significance criteria provided, multiple submitters, no conflicts U:3

Conservation

PhyloP100: 3.54

Publications

0 publications found
Variant links:
Genes affected
TRDN (HGNC:12261): (triadin) This gene encodes an integral membrane protein found in skeletal and cardiac muscle. The encoded protein plays a role in skeletal muscle excitation-contraction coupling as part of the calcium release complex and is required for normal skeletal muscle strength. This protein indirectly links triads and microtubules in skeletal muscle. Mutations in this gene are associated with cardiac arrythmia syndrome and some variants in this gene may be associated with sudden cardiac death. [provided by RefSeq, May 2022]
TRDN Gene-Disease associations (from GenCC):
  • catecholaminergic polymorphic ventricular tachycardia
    Inheritance: AD, AR Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
  • catecholaminergic polymorphic ventricular tachycardia 5
    Inheritance: AR Classification: DEFINITIVE, STRONG Submitted by: Labcorp Genetics (formerly Invitae), G2P, Genomics England PanelApp
  • familial long QT syndrome
    Inheritance: AR Classification: STRONG Submitted by: G2P
  • long QT syndrome
    Inheritance: AR Classification: STRONG Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Uncertain_significance. The variant received 4 ACMG points.

PP3
Splicing predictors support a deleterious effect. Scorers claiming Pathogenic: dbscSNV1_ADA, dbscSNV1_RF, max_spliceai. No scorers claiming Uncertain. No scorers claiming Benign.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
TRDNNM_006073.4 linkc.1783G>A p.Asp595Asn missense_variant, splice_region_variant Exon 32 of 41 ENST00000334268.9 NP_006064.2 Q13061-1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
TRDNENST00000334268.9 linkc.1783G>A p.Asp595Asn missense_variant, splice_region_variant Exon 32 of 41 1 NM_006073.4 ENSP00000333984.5 Q13061-1

Frequencies

GnomAD3 genomes
AF:
0.0000263
AC:
4
AN:
151844
Hom.:
0
Cov.:
31
show subpopulations
Gnomad AFR
AF:
0.00
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.0000657
Gnomad ASJ
AF:
0.00
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00
Gnomad FIN
AF:
0.00
Gnomad MID
AF:
0.00
Gnomad NFE
AF:
0.0000294
Gnomad OTH
AF:
0.000479
GnomAD2 exomes
AF:
0.0000201
AC:
4
AN:
198842
AF XY:
0.0000187
show subpopulations
Gnomad AFR exome
AF:
0.00
Gnomad AMR exome
AF:
0.0000363
Gnomad ASJ exome
AF:
0.000116
Gnomad EAS exome
AF:
0.00
Gnomad FIN exome
AF:
0.00
Gnomad NFE exome
AF:
0.0000227
Gnomad OTH exome
AF:
0.00
GnomAD4 exome
AF:
0.0000269
AC:
38
AN:
1413916
Hom.:
0
Cov.:
28
AF XY:
0.0000314
AC XY:
22
AN XY:
700916
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
31400
American (AMR)
AF:
0.0000517
AC:
2
AN:
38678
Ashkenazi Jewish (ASJ)
AF:
0.0000402
AC:
1
AN:
24892
East Asian (EAS)
AF:
0.00
AC:
0
AN:
37926
South Asian (SAS)
AF:
0.00
AC:
0
AN:
78252
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
51618
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
5562
European-Non Finnish (NFE)
AF:
0.0000304
AC:
33
AN:
1087296
Other (OTH)
AF:
0.0000343
AC:
2
AN:
58292
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.470
Heterozygous variant carriers
0
3
6
9
12
15
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Exome Het
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome
AF:
0.0000263
AC:
4
AN:
151844
Hom.:
0
Cov.:
31
AF XY:
0.0000270
AC XY:
2
AN XY:
74152
show subpopulations
African (AFR)
AF:
0.00
AC:
0
AN:
41340
American (AMR)
AF:
0.0000657
AC:
1
AN:
15226
Ashkenazi Jewish (ASJ)
AF:
0.00
AC:
0
AN:
3468
East Asian (EAS)
AF:
0.00
AC:
0
AN:
5180
South Asian (SAS)
AF:
0.00
AC:
0
AN:
4822
European-Finnish (FIN)
AF:
0.00
AC:
0
AN:
10576
Middle Eastern (MID)
AF:
0.00
AC:
0
AN:
316
European-Non Finnish (NFE)
AF:
0.0000294
AC:
2
AN:
67922
Other (OTH)
AF:
0.000479
AC:
1
AN:
2086
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.550
Heterozygous variant carriers
0
1
1
2
2
3
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Variant carriers
0
2
4
6
8
10
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0000676
Hom.:
0
Bravo
AF:
0.0000113
ExAC
AF:
0.00000832
AC:
1

ClinVar

Significance: Uncertain significance
Submissions summary: Uncertain:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link

Submissions by phenotype

Catecholaminergic polymorphic ventricular tachycardia 1;C3809536:Catecholaminergic polymorphic ventricular tachycardia 5 Uncertain:1
Sep 10, 2021
Fulgent Genetics, Fulgent Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

- -

Catecholaminergic polymorphic ventricular tachycardia 1 Uncertain:1
Apr 25, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

This sequence change replaces aspartic acid, which is acidic and polar, with asparagine, which is neutral and polar, at codon 595 of the TRDN protein (p.Asp595Asn). This variant also falls at the last nucleotide of exon 32, which is part of the consensus splice site for this exon. This variant is present in population databases (rs771170294, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with TRDN-related conditions. ClinVar contains an entry for this variant (Variation ID: 532385). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Cardiovascular phenotype Uncertain:1
Dec 13, 2023
Ambry Genetics
Significance:Uncertain significance
Review Status:criteria provided, single submitter
Collection Method:clinical testing

The c.1783G>A variant (also known as p.D595N), located in coding exon 32 of the TRDN gene, results from a G to A substitution at nucleotide position 1783. The amino acid change results in aspartic acid to asparagine at codon 595, an amino acid with highly similar properties. However, this change occurs in the last base pair of coding exon 32, which makes it likely to have some effect on normal mRNA splicing. This nucleotide position is highly conserved in available vertebrate species. This amino acid position is well conserved in available vertebrate species. In silico splice site analysis predicts that this alteration will weaken the native splice donor site. In addition, as a missense substitution, this is predicted to be tolerated by in silico analysis. This alteration does not impact the predominant cardiac isoform of TRDN (NM_001256021.1; Kobayashi YM et al. J. Biol. Chem., 1999 Oct;274:28660-8). Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
0.097
BayesDel_addAF
Benign
-0.35
T
BayesDel_noAF
Benign
-0.62
CADD
Pathogenic
30
DANN
Uncertain
1.0
DEOGEN2
Benign
0.11
T
Eigen
Benign
0.14
Eigen_PC
Benign
0.16
FATHMM_MKL
Uncertain
0.83
D
LIST_S2
Benign
0.62
T
M_CAP
Benign
0.012
T
MetaRNN
Benign
0.21
T
MetaSVM
Benign
-1.1
T
MutationAssessor
Benign
0.90
L
PhyloP100
3.5
PrimateAI
Benign
0.41
T
PROVEAN
Benign
0.070
N
REVEL
Benign
0.11
Sift
Uncertain
0.0040
D
Sift4G
Benign
0.16
T
Polyphen
0.91
P
Vest4
0.15
MutPred
0.40
Loss of ubiquitination at K593 (P = 0.044);
MVP
0.26
ClinPred
0.40
T
GERP RS
4.1
Varity_R
0.10
gMVP
0.027
Mutation Taster
=54/46
polymorphism

Splicing

Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Pathogenic
1.0
dbscSNV1_RF
Pathogenic
1.0
SpliceAI score (max)
0.70
Details are displayed if max score is > 0.2
DS_DL_spliceai
0.70
Position offset: 0

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs771170294; hg19: chr6-123588852; API